Deleted Tweet from Scott Gottlieb, R-D.C.
Deleted Tweet from Scott Gottlieb, M.D.
SteveFDA (R-D.C.)
@SGottliebFDA
Politwoops no longer follows this account.
The reduced need for multiple large clinical outcomes studies as a part of biosimilar product development can significantly lower development costs. This can result in significantly lower prices for patients and payors, as is already seen in Europe https://t.co/ZZTMQgohIZ https://t.co/cJAfGCBblg
It looks like this tweet was replaced by the next tweet from @SGottliebFDA.